Oversubscribed $275M private placement drives ENTX

 

• Entera Bio priced $275M oversubscribed private placement at $2.04/share on July 27, 2026.
• Led by BVF Partners with top investors including RA Capital, Perceptive, Venrock, Longitude, Vivo.
• Proceeds fully fund Phase 3 registrational study for EB613 oral anabolic tablet in osteoporosis.
• Extends cash runway into 2030 and advances EB612 hypoparathyroidism program to Phase 1.
• Builds on positive FDA feedback received in June 2026 on 12-month Phase 3 protocol using BMD endpoint.
• Issuance of ~123M shares plus pre-funded warrants; deal expected to close July 28.
• Signals strong institutional validation of Entera’s oral peptide platform per GlobeNewswire release.

https://finviz.com/stock?t=ENTX&p=d